Advertisement

Uterine Cancer pp 223-233 | Cite as

Treatment of Advanced and Recurrent Carcinoma: Chemotherapy

  • Fernanda MusaEmail author
Part of the Current Clinical Oncology book series (CCO)

Abstract

Chemotherapy for endometrial cancer has evolved over the past two decades, with drug combinations convincingly showing to have a role in the treatment of advanced and recurrent endometrial cancer. Agents with established antitumor activity include doxorubicin, cisplatin, and paclitaxel. A combination of paclitaxel with the cisplatin analog carboplatin is currently the most commonly used regimen for first-line treatment of metastatic disease. Questions remain about the contribution of these regimens in adjuvant settings, about the role of drug therapy beyond first-line treatments, and about integration of targeted agents.

Keywords

Endometrial Chemotherapy Doxorubicin Cisplatin Paclitaxel Carboplatin 

References

  1. 1.
    Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10:31–46.CrossRefGoogle Scholar
  2. 2.
    Randall ME, Spirtos NM, Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr. 1995;19:13–5.Google Scholar
  3. 3.
    Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95:266–71.CrossRefGoogle Scholar
  4. 4.
    Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–33.CrossRefGoogle Scholar
  5. 5.
    Hogberg T. Adjuvant chemotherapy in endometrial cancer. Int J Gynecol Cancer. 2010;20:S57–9.CrossRefGoogle Scholar
  6. 6.
    Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:543–52.CrossRefGoogle Scholar
  7. 7.
    Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev. 2014;5, CD010681.Google Scholar
  8. 8.
    Goff BA, Goodman A, Muntz HG, Fuller Jr AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol. 1994;52:237–40.CrossRefGoogle Scholar
  9. 9.
    Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol. 1997;67:56–60.CrossRefGoogle Scholar
  10. 10.
    Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78:85–91.CrossRefGoogle Scholar
  11. 11.
    Memarzadeh S, Holschneider CH, Bristow RE, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer. 2002;12:454–8.CrossRefGoogle Scholar
  12. 12.
    Lambrou NC, Gomez-Marin O, Mirhashemi R, et al. Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol. 2004;93:653–8.CrossRefGoogle Scholar
  13. 13.
    Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:190–3.CrossRefGoogle Scholar
  14. 14.
    Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer. 2009;101:244–9.CrossRefGoogle Scholar
  15. 15.
    Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1408–14.CrossRefGoogle Scholar
  16. 16.
    Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:3902–8.CrossRefGoogle Scholar
  17. 17.
    Aapro M. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group. Semin Oncol. 1998;25:7–11.PubMedGoogle Scholar
  18. 18.
    Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3808–13.CrossRefGoogle Scholar
  19. 19.
    Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15:1173–8.CrossRefGoogle Scholar
  20. 20.
    Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159–66.CrossRefGoogle Scholar
  21. 21.
    Miller DFV, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;3:771–3.CrossRefGoogle Scholar
  22. 22.
    Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19:4048–53.CrossRefGoogle Scholar
  23. 23.
    Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008;18:803–8.CrossRefGoogle Scholar
  24. 24.
    Scudder SA, Liu PY, Wilczynski SP, et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol. 2005;96:610–5.CrossRefGoogle Scholar
  25. 25.
    Arimoto T, Nakagawa S, Yasugi T, et al. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2007;104:32–5.CrossRefGoogle Scholar
  26. 26.
    Goldfinger M, Diaz I, Muggia F. Systemic treatment of endometrial cancer: what is doxorubicin’s role? J Clin Oncol. 2014;32:2181–2.CrossRefGoogle Scholar
  27. 27.
    van Wijk FH, Lhomme C, Bolis G, et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer. 2003;39:78–85.CrossRefGoogle Scholar
  28. 28.
    Trope C, Grundsell H, Johnsson JE, Cavallin-Stahl E. A phase II study of Cis-platinum for recurrent corpus cancer. Eur J Cancer. 1980;16:1025–6.CrossRefGoogle Scholar
  29. 29.
    Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984;7:253–6.CrossRefGoogle Scholar
  30. 30.
    Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;33:68–70.CrossRefGoogle Scholar
  31. 31.
    Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. 1982;59:225–8.PubMedGoogle Scholar
  32. 32.
    Edmonson JH, Krook JE, Hilton JF, et al. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol. 1987;28:20–4.CrossRefGoogle Scholar
  33. 33.
    Deppe G, Cohen CJ, Bruckner HW. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiamine platinum (II) after intensive prior therapy. Gynecol Oncol. 1980;10:51–4.CrossRefGoogle Scholar
  34. 34.
    Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep. 1978;62:159–61.PubMedGoogle Scholar
  35. 35.
    Pawinski A, Tumolo S, Hoesel G, et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol. 1999;86:179–83.CrossRefGoogle Scholar
  36. 36.
    Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999;75:473–5.CrossRefGoogle Scholar
  37. 37.
    Gunthert AR, Ackermann S, Beckmann MW, et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol. 2007;104:86–90.CrossRefGoogle Scholar
  38. 38.
    Katsumata N, Noda K, Nozawa S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer. 2005;93:999–1004.CrossRefGoogle Scholar
  39. 39.
    Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979;63:21–7.PubMedGoogle Scholar
  40. 40.
    Calero F, Asins-Codoner E, Jimeno J, et al. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer. 1991;27:864–6.CrossRefGoogle Scholar
  41. 41.
    Fracasso PM, Blessing JA, Molpus KL, Adler LM, Sorosky JI, Rose PG. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;103:523–6.CrossRefGoogle Scholar
  42. 42.
    Homesley HD, Blessing JA, Sorosky J, Reid G, Look KY. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005;98:294–8.CrossRefGoogle Scholar
  43. 43.
    Balbi G, Visconti S, Monteverde A, Manganaro MA, Cardone A. Liposomal doxorubicin: a phase II trial. Acta Biomed. 2007;78:210–3.PubMedGoogle Scholar
  44. 44.
    Escobar PF, Markman M, Zanotti K, Webster K, Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol. 2003;129:651–4.CrossRefGoogle Scholar
  45. 45.
    Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2002;20:2360–4.CrossRefGoogle Scholar
  46. 46.
    Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996;7:861–3.CrossRefGoogle Scholar
  47. 47.
    Woo HL, Swenerton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol. 1996;19:290–1.CrossRefGoogle Scholar
  48. 48.
    Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2003;88:277–81.CrossRefGoogle Scholar
  49. 49.
    Hirai Y, Hasumi K, Onose R, et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecol Oncol. 2004;94:471–6.CrossRefGoogle Scholar
  50. 50.
    Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol. 1996;62:278–81.CrossRefGoogle Scholar
  51. 51.
    Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002;87:247–51.CrossRefGoogle Scholar
  52. 52.
    Wadler S, Levy DE, Lincoln ST, Soori GS, Schink JC, Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21:2110–4.CrossRefGoogle Scholar
  53. 53.
    Brown J, Smith JA, Ramondetta LM, et al. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010;116:4973–9.CrossRefGoogle Scholar
  54. 54.
    McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138:18–23.CrossRefGoogle Scholar
  55. 55.
    Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Freedman RS, Wharton JT. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer. 1987;59:1264–7.CrossRefGoogle Scholar
  56. 56.
    Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–32.CrossRefGoogle Scholar
  57. 57.
    Thigpen JT, Kronmal R, Vogel S, et al. A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study. Am J Clin Oncol. 1987;10:429–31.CrossRefGoogle Scholar
  58. 58.
    Thigpen JT, Blessing JA, Orr Jr JW, DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep. 1986;70:271–4.PubMedGoogle Scholar
  59. 59.
    Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group Study). Am J Obstet Gynecol. 1989;161:309–12.CrossRefGoogle Scholar
  60. 60.
    Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2001;83:268–70.CrossRefGoogle Scholar
  61. 61.
    Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol. 2000;79:147–53.CrossRefGoogle Scholar
  62. 62.
    Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:526–31.CrossRefGoogle Scholar
  63. 63.
    Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. J Clin Oncol. 2010;28:2727–31.CrossRefGoogle Scholar
  64. 64.
    Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136:246–53.CrossRefGoogle Scholar
  65. 65.
    Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33:930–6.CrossRefGoogle Scholar
  66. 66.
    Slayton RE, Blessing JA, Delgado G. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Cancer Treat Rep. 1982;66:1669–71.PubMedGoogle Scholar
  67. 67.
    Poplin EA, Liu PY, Delmore JE, et al. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a Southwest Oncology Group Study. Gynecol Oncol. 1999;74:432–5.CrossRefGoogle Scholar
  68. 68.
    Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1996;63:101–4.CrossRefGoogle Scholar
  69. 69.
    Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996;63:25–7.CrossRefGoogle Scholar
  70. 70.
    Tait DL, Blessing JA, Hoffman JS, et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011;121:118–21.CrossRefGoogle Scholar
  71. 71.
    Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study. Cancer. 1994;73:1453–5.CrossRefGoogle Scholar
  72. 72.
    Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P, Alvarez RD. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol. 2009;27:3104–8.CrossRefGoogle Scholar
  73. 73.
    Muss HB, Blessing JA, Hatch KD, Soper JT, Webster KD, Kemp GM. Methotrexate in advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol. 1990;13:61–3.CrossRefGoogle Scholar
  74. 74.
    Broun GO, Blessing JA, Eddy GL, Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1993;16:18–21.CrossRefGoogle Scholar
  75. 75.
    Jackson Jr DV, Jobson VW, Homesley HD, et al. Vincristine infusion in refractory gynecologic malignancies. Gynecol Oncol. 1986;25:212–6.CrossRefGoogle Scholar
  76. 76.
    Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol. 2012;36:753–61.CrossRefGoogle Scholar
  77. 77.
    Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26:4319–25.CrossRefGoogle Scholar
  78. 78.
    Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116:15–20.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Gynecologic OncologyNew York University Langone Medical CenterNew YorkUSA

Personalised recommendations